FL-SINTAVIA-LLC
17.3.2021 13:01:05 CET | Business Wire | Press release
Sintavia, LLC , a designer and 3D printer of a new generation of flight and launch components, announced today that it had published an overview of proper handling procedures for powder condensate waste generated as part of the powder bed fusion additive manufacturing process. The paper, titled, “Overview of Disposal Procedures for Powder Condensate” was written by Sintavia’s Quality & EHS Engineer, Ashley Wallace, in collaboration with the Additive Manufacturer Green Trade Association (AMGTA) and Triumvirate Environmental .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005082/en/
Powder condensate is the term used to describe solidified particles resulting from the evaporation of metal alloys during the powder bed fusion additive manufacturing (AM) process. This condensate, which is a waste stream unique to AM, is either deposited into a collection chamber within the AM printer (considered to be “dry” condensate) or wet-vacuumed out of the build chamber itself (considered, along with melt spatter contemporaneously removed, to be “wet” condensate). Both wet and dry condensate may be hazardous and must be disposed of pursuant to applicable environmental regulations. As metal AM is only now entering maturity with respect to production, powder condensate as a waste stream has previously neither been a major concern for operators nor studied widely. However, high volume manufacturers increasingly need to allocate proper resources for the safe disposal of this material. In order to do so, powder condensate should be classified as a separate waste stream and documented appropriately with cost-effective methods for its disposal. This paper discusses the procedures used in the United States for analyzing and disposing of condensate from the powder bed fusion process, and provides a real world example of how one high-volume manufacturer handles this disposal
According to its author, “knowing where each condensate stream is going is just as important as the proper preparation of each type of waste. As Sintavia has grown, we have recognized that proper disposal of all of our waste streams must be a priority. We have worked with Triumvirate Environmental and other experts within the industry to manage the final disposal of these streams according to regulatory requirements.” The full paper is available to AMGTA member companies, other industry stakeholders, and the general public on the AMGTA website at: https://www.amgta.org/resources/ .
“We were pleased to work with the Additive Manufacturer Green Trade Association and Triumvirate Environmental on this paper,” said Brian Neff, Sintavia’s Chief Executive Officer. “By sharing what we’ve learned with other industry stakeholders, we hope these published guidelines can help other powder bed fusion AM manufacturers as they develop their own process to determine the safe and proper handling and disposal of powder condensate.”
About Sintavia
Sintavia designs and 3D prints a new generation of flight and launch products for the Aerospace, Defense, & Space industry. The company's ability to design and serially produce thermally engineered components with complex structural walls of less than 150 microns has unlocked a level of performance impossible to achieve using traditional manufacturing methods. With 30 high-speed printers co-located alongside precision post processing equipment, a full complement of mechanical testing equipment, and a full metallurgical and powder laboratory, Sintavia is able to optimize parameters, serially manufacture, and audit quality parts for aerospace applications. A founding member of the Additive Manufacturer Green Trade Association, Sintavia is committed to the highest quality standards in the industry and holds multiple Nadcap and other aerospace accreditations. For more information, visit https://sintavia.com/ .
About AMGTA
The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process. Founding Members of the AMGTA include ExOne , Sintavia, LLC , Taiyo Nippon Sanso Corporation and QC Laboratories, Inc. Participating Members of the AMGTA include AMEXCI AB , BASF 3D Printing Solutions , Danish AM Hub , DyeMansion , EOS , Fraunhofer Institute for Laser Technology (ILT) , GE Additive , HP, Inc. , Materialise , National Manufacturing Institute Scotland , Rusal America , Siemens Digital Industries Software , SLM Solutions Inc. , Stryker , The Barnes Global Advisors , TRUMPF , and 6K . For more information, please contact Sherry Handel, at +1 954.308.0888, or visit www.amgta.org .
About Triumvirate Environmental
Triumvirate Environmental is a leading provider of enterprise waste management and environmental services to Healthcare, Education, Life Sciences and Industrial markets. It prides itself on its attention to safety, sustainability, and innovative solutions. Service offerings include environmental waste reduction, waste management plan creation and implementation, and green and sustainable solution development. Learn more at www.triumvirate.com or call us at 888-834-9697.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
